Abstract
Bacteriophages, which lost out to antibiotic therapy in the past, may be poised to make a comeback. Once discarded because of their narrow activity spectrum, it can now be viewed as a major advantage that these intracellular, self-replicating entities can exert their killing effect with minimal damage to the commensal microbiome. In eastern Europe, phages continue to be used both prophylactically and therapeutically to treat infections. More recently, much needed regulated clinical trials are underway with a view to restoring phage therapy as a tool for mainstream medicine, although current regulations may impede their full potential.
| Original language | English |
|---|---|
| Pages (from-to) | 711-726 |
| Number of pages | 16 |
| Journal | Future Microbiology |
| Volume | 13 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - May 2018 |
Keywords
- antibiotic resistance
- bacteriophage
- clinical trials
- Escherichia coli
- phage resistance
- Pseudomonas aeruginosa
- Staphylococcus aureus
Fingerprint
Dive into the research topics of 'Phages & antibiotic resistance: Are the most abundant entities on earth ready for a comeback?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver